Speakers
Dr Andrew Breen
Breakout session
In this breakout session, ICCQIP Chair Tom Hellyer will provide an overview of the Infection in Critical Care Quality Improvement Programme (ICCQIP). The presentation will highlight the importance of infection surveillance in critical care, with a focus on ICCQIP’s role in monitoring bloodstream infections and supporting quality improvement.
Chair: Andrew Breen
Presentation:
Andy is a consultant in ICM working in Leeds Teaching Hospitals, having been appointed in 2005. He is Clinical Director for Adult Critical Care in Leeds, and President Elect of the Intensive Care Society. He graduated in Liverpool in 1995, where he completed his clinical training in anaesthesia and intensive care medicine.
Andy has strong interest in point-of-care ultrasound, having been a founding member of the FICE committee, current member of the FUSIC committee and co-author of a number of POCUS accreditation programmes. Other interests include ethical decision making and advance care planning, the science of quality improvement and IV fluids education.
Senior clinical fellow / honorary consultant critical care medicine.
I am a clinician scientist in critical care medicine at Newcastle University and my clinical practice is based in the Royal Victoria Infirmary intensive care department. My research focuses on improving antibiotic stewardship in critically ill patients. Striking the right balance of effectively treating patients with severe infections while avoiding harms associated with antibiotic overuse, is challenging for critically ill patients.
My current research focuses on optimising antibiotic durations in patients with sepsis. RISC-sepsis is an NIHR EME funded project that is an embedded mechanistic trial within a large pragmatic RCT. We immune phenotype patients to determine whether sepsis-induced immune dysfunction impacts antibiotic stewardship interventions. SHORTER is an NIHR HTA funded pragmatic RCT that aims to determine whether short, fixed-course antibiotics (5 days) are safe and effective in critically ill patients with sepsis.